GlassScriptPhysician profile
Richa Dhungana
NPI 1922776533
$1,419.54
in general payments reported to CMS, 2019-2025
22 companies · $526 in 2025
The $526 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $145 · 2023: $453 · 2024: $296 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $525.46 | 2022-2025 | Keytruda, Zerbaxa, Dificid |
| Alexion Pharmaceuticals, INC. | $111.60 | 2023-2025 | Ultomiris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.53 | 2024-2025 | Xifaxan |
| Janssen Biotech, INC. | $81.14 | 2023-2025 | Darzalex, Imbruvica, Tecvayli |
| Janssen Pharmaceuticals, INC | $65.34 | 2022-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.77 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $58.24 | 2024 | Lynparza, Enhertu |
| Incyte Corporation | $56.77 | 2023-2025 | Jakafi, Niktimvo, Pemazyre |
| Abbvie INC. | $55.52 | 2022 | |
| Amgen INC. | $40.09 | 2023 | Blincyto, Kyprolis, Repatha |
| Melinta Therapeutics, LLC | $30.94 | 2025 | Orbactiv, Kimyrsa, Rezzayo |
| Stryker Corporation | $29.57 | 2025 | Flowtriever |
| Argenx US, INC. | $27.32 | 2023 | Vyvgart |
| Pfizer INC. | $25.23 | 2022 | |
| Eisai INC. | $21.53 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $20.20 | 2023 | Veklury |
| Seagen INC. | $19.93 | 2023 | Padcev |
| Urgo Medical North America, LLC | $16.06 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Masimo Corporation | $15.34 | 2023 | Set and Rainbow Set, Sedline |
| Bioxcel Therapeutics, INC. | $14.96 | 2023 | Igalmi |
| Mallinckrodt Hospital Products INC. | $14.76 | 2025 | Terlivaz |
| E.R. Squibb & Sons, L.L.C. | $13.24 | 2024 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richa Dhungana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.